Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Mydecine Innovations Group Inc (MYCOF) Message Board

Study Finds That Patients with Childhood Trauma Ma

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 160
(Total Views: 195)
Posted On: 01/28/2022 4:41:58 PM
Avatar
Posted By: NetworkNewsWire
Study Finds That Patients with Childhood Trauma May Benefit from PTSD Treatment

A new study has found that adults who were mistreated or abused as children and suffer from PTSD as a result of this may benefit from cognitive behavioral therapy. The study was carried out by a team of 15 therapists led by Danielle Oprel, a clinical psychologist, and Chris Hoeber, a PhD candidate and researcher. The researchers are hopeful about the perspective the study’s findings provide to individuals with serious PTSD symptoms.

Hoeber’s objective was to determine which form of prolonged exposure therapy was the most effective for this particular group. The study was comprised of 149 patients, most of whom had been suffering from PTSD symptoms for years. Hoeber studied three variants, which involved comparing the standard one to an intensive variant. The standard variant involved weekly consultations for PTSD with a therapist while the intensive one involved three consultations every week. In the third approach, patients were taught skills such as emotion regulation to help them cope better with the prolonged exposure treatment.

Hoeber discovered that while all the forms of therapy worked well, patients who underwent intensive therapy were symptom free sooner. About one-half of the patients presented with no symptoms of PTSD after treatment, with the researchers noting a clear improvement in another quarter and no improvement in the remaining quarter.

Prolonged exposure therapy is a behavioral therapy method that is effective in treating post-traumatic stress disorder. It involves a patient recounting a traumatic memory vividly, under the supervision of a therapist. The therapist asks questions about the sounds, sights and smells connected to the experience as the patient recounts the memory in present tense, in the first person.

This technique allows individuals to learn that they are safe and can cope with those memories without having to block or avoid them. The therapist can also give the patient assignments to help control avoidant behavior.

Despite being effective, prolonged exposure therapy is not used to treat PTSD in individuals who were mistreated or abused as children. In cases like this, the treatment used primarily deals with the additional symptoms.

Hoeber explained that most practitioners believed that people who have been abused are so vulnerable that they couldn’t cope with reliving the experiences and that this technique would trigger a crisis or increase the trauma, which wasn’t always the case.

The researchers are focused on improving their treatment in order to help the group that saw no improvement in their symptoms. In the report, Hoeber stated that it was crucial that therapists use the prolonged exposure therapy to provide proper treatment to such patients.

Many companies, including Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF), are hard at work looking to develop new medications to combat various mental health conditions, such as PTSD.

NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer



(0)
(0)




Mydecine Innovations Group Inc (MYCOF) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us